These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 10744007)

  • 41. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency.
    Roztocil K; Stvrtinová V; Strejcek J
    Int Angiol; 2003 Mar; 22(1):24-31. PubMed ID: 12771852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparative capillaroscopic study of certain bioflavonoids and total triterpenic fractions of Centella asiatica in venous insufficiency].
    Allegra C
    Clin Ter; 1984 Sep; 110(6):555-9. PubMed ID: 6238770
    [No Abstract]   [Full Text] [Related]  

  • 43. Rational therapy of chronic venous insufficiency--chances and limits of the therapeutic use of horse-chestnut seeds extract.
    Ottillinger B; Greeske K
    BMC Cardiovasc Disord; 2001; 1():5. PubMed ID: 11747472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency.
    Belcaro G; Cesarone MR; de Sanctis MT; Incandela L; Laurora G; Février B; Wargon C; De Gregoris P
    Int J Microcirc Clin Exp; 1995; 15 Suppl 1():45-9. PubMed ID: 8748889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Semisynthetic Diosmin (Phlebodia 600) for therapy of lower limb chronic venous insufficiency].
    Kirienko AI; Bogachev VIu; Zolotukhin IA; Golovanova OV
    Angiol Sosud Khir; 2006; 12(2):73-5. PubMed ID: 17053765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. At the Crossroads of Venous Insufficiency and Hemorrhoidal Disease: Daflon 500 mg. Proceedings of a symposium. Vienna, Austria, January 31, 1992.
    Angiology; 1994 Jun; 45(6 Pt 2):493-584. PubMed ID: 7911285
    [No Abstract]   [Full Text] [Related]  

  • 47. [The chronobiology and clinical efficacy of Daflon in the treatment of chronic venous insufficiency].
    Menyhelyi G; Acsády G; Hetényi A; Dubeaux D; Radó G
    Ter Arkh; 1997; 69(4):46-8. PubMed ID: 9213959
    [No Abstract]   [Full Text] [Related]  

  • 48. Clinical improvement in chronic venous insufficiency signs and symptoms with Venoruton® (HR): an 8-month, open-registry, cost-efficacy study.
    Cesarone MR; Belcaro G; Ippolito E; Pellegrini L; Ledda A; Luzzi R; Ricci A; Dugall M; Bavera P; Hosoi M; Stuard S; Corsi M
    Panminerva Med; 2010 Jun; 52(2 Suppl 1):43-8. PubMed ID: 20657534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg.
    Laurent R; Gilly R; Frileux C
    Int Angiol; 1988; 7(2 Suppl):39-43. PubMed ID: 3053942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Horse-chestnut seed extract for chronic venous insufficiency.
    Bielanski TE; Piotrowski ZH
    J Fam Pract; 1999 Mar; 48(3):171-2. PubMed ID: 10086755
    [No Abstract]   [Full Text] [Related]  

  • 51. Daflon 500 mg: symptoms and edema clinical update.
    Ramelet AA
    Angiology; 2005; 56 Suppl 1():S25-32. PubMed ID: 16193223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
    Meyer OC
    Angiology; 1994 Jun; 45(6 Pt 2):579-84. PubMed ID: 8203791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Evaluation of internally effective venous drugs].
    Friederich HC; Vogelsberg H; Neiss A
    Z Hautkr; 1978 Jun; 53(11):369-74. PubMed ID: 351993
    [No Abstract]   [Full Text] [Related]  

  • 54. A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency.
    Bergqvist D; Hallböök T; Lindblad B; Lindhagen A
    Vasa; 1981; 10(3):253-60. PubMed ID: 7025500
    [No Abstract]   [Full Text] [Related]  

  • 55. Oxerutins (Venoruton): efficacy in chronic venous insufficiency--a double-blind, randomized, controlled study.
    Petruzzellis V; Troccoli T; Candiani C; Guarisco R; Lospalluti M; Belcaro G; Dugall M
    Angiology; 2002; 53(3):257-63. PubMed ID: 12025912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg.
    Duchene Marullaz P; Amiel M; Barbe R
    Int Angiol; 1988; 7(2 Suppl):25-32. PubMed ID: 3053940
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial.
    Belczak SQ; Sincos IR; Campos W; Beserra J; Nering G; Aun R
    Phlebology; 2014 Aug; 29(7):454-60. PubMed ID: 23761871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chronic diarrhea and lymphocytic colitis associated with Daflon therapy].
    Mennecier D; Saloum T; Roycourt AM; Nexon MH; Thiolet C; Farret O
    Gastroenterol Clin Biol; 1999 Oct; 23(10):1101-2. PubMed ID: 10592888
    [No Abstract]   [Full Text] [Related]  

  • 59. O-(beta-hydroxyethyl)-rutosides (Paroven; Venoruton): new studies, improved safety, and novel cardiovascular applications.
    Cesarone MR; Belcaro G; Grossi MG
    Angiology; 2008; 59 Suppl 1():5S-6S. PubMed ID: 18287161
    [No Abstract]   [Full Text] [Related]  

  • 60. Vital capillaroscopy on microcirculation: pharmacodynamic activity of Daflon 500 mg in venous insufficiency.
    Balas P; Pagratis N
    Int Angiol; 1989; 8(4 Suppl):51-2. PubMed ID: 2632650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.